Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NA-931 Alone or With Tirzepatide in Overweight or Obese Men and Women
NCT06732245Phase 2Not yet recruiting
- Sponsor
- Biomed Industries
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of NA-931 in obesity, Overweight, sponsored by Biomed Industries. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
NA-931
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06732245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732245.